Human Genome Sciences (HGSI) Calls It; Says July 16th Deadline for Bids (GSK)

Article Stock Quotes (2) Comments (0)

Human Genome Sciences, Inc. (Nasdaq: HGSI) announced that, in connection with its ongoing strategic alternative review process, it had previously set a bid date of July 16, 2012 for the submission of definitive proposals to acquire all outstanding common shares of HGS. In this regard, HGS yesterday sent a letter to GlaxoSmithKline (NYSE: GSK) once again inviting GSK to participate in the ongoing process according to the same procedures previously established and to provide, by no later than July 16, 2012, GSK’s final bid terms, including a response to a draft agreement which will be provided to all interested bidders. The letter specifically noted that the HGS Board of Directors has previously rejected $13.00 per share as inadequate.

HGS is committed to completing its exploration of strategic alternatives in a manner that ensures that HGS stockholders have the benefit of a complete and fair process and welcomes GSK to fully participate in such process.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• UPDATE: Liberty Global (LBTYA) Interested in Kabel Deutschland - FT
• Globus Medical (GMED) Receives Unfavorable Verdict in Synthes Patent Case
• Elan Corp (ELN) Shareholders Approve Buyback; Three Transactions Voted Down (THRX)

Create E-mail Alert Related Categories

Corporate News, Mergers and Acquisitions

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?